natgillin/translations-raw huggingface dataset:
Published data show that differences of this size in concentration of the active substance, flavour and amount of cyclodextrins do not affect how the medicine works. 
Objavljeni podatki kažejo, da takšna velikost razlik v koncentraciji učinkovine, okusu in količini ciklodekstrinov ne vpliva na delovanje zdravila.
Having reviewed the available data, EMA considered that differences between Flurbiprofen Geiser and Strefen Direct are minor and do not affect the amount of active substance that is released in the mouth and into the bloodstream. 
Po pregledu razpoložljivih podatkov je agencija EMA ocenila, da so razlike med zdraviloma Flurbiprofen Geiser in Strefen Direct manjše in da ne vplivajo na količino učinkovine, ki se sprosti v ustih in v krvni obtok.
Flurbiprofen Geiser is a medicine used for the short-term relief of symptoms of sore throat. 
Flurbiprofen Geiser je zdravilo, ki se uporablja za kratkotrajno lajšanje simptomov vnetega žrela.
Based on evaluation of the currently available data, the Agency concluded that the benefits of Flurbiprofen Geiser outweigh its risks, and therefore the marketing authorisation for Flurbiprofen Geiser should be granted in all concerned Member States. 
Agencija je na podlagi vrednotenja trenutno razpoložljivih podatkov zaključila, da koristi zdravila Flurbiprofen Geiser odtehtajo z njim povezana tveganja in da se dovoljenje za promet s tem zdravilom izda v vseh zadevnih državah članicah.
On 17 October 2019, the European Medicines Agency completed a review of Flurbiprofen Geiser following a disagreement among EU Member States regarding its authorisation. 
Evropska agencija za zdravila je 17. oktobra 2019 zaključila pregled v zvezi z izdajo dovoljenja za promet z zdravilom Flurbiprofen Geiser po nesoglasju med državami članicami EU.
The European Commission issued an EU-wide legally binding decision on the marketing authorisation of Flurbiprofen Geiser on 16/12/2019. 
Evropska komisija je 16. 12. 2019 izdala končni pravno zavezujoči sklep, ki velja po vsej EU, o izdaji dovoljenja za promet z zdravilom Flurbiprofen Geiser.
In addition Flurbiprofen Geiser has a different flavour and contains smaller amounts of substances called cyclodextrins, which help to stabilise the solution. 
Poleg tega ima zdravilo Flurbiprofen Geiser drugačen okus in vsebuje manj snovi, imenovanih ciklodekstrini, ki pomagajo stabilizirati raztopino.
However, the reference medicine, Strefen Direct, has a different concentration to Flurbiprofen Geiser. 
Vendar pa je koncentracija referenčnega zdravila Strefen Direct drugačna od koncentracije zdravila Flurbiprofen Geiser.
The medicines also have different flavours and different amounts of cyclodextrins and this could affect how the active substance is taken up into the body. 
Zdravili sta tudi drugačnega okusa in vsebujeta različni količini ciklodekstrinov, kar bi lahko vplivalo na privzem učinkovine v telo.
What is Flurbiprofen Geiser? 
Kaj je zdravilo Flurbiprofen Geiser?
submitted Flurbiprofen Geiser to the Spanish medicines agency for a decentralised procedure. 
je španski agenciji za zdravila predložilo vlogo za izdajo dovoljenja za zdravilo Flurbiprofen Geiser po decentraliziranem postopku.
Name Strength Pharmaceutical Form 
Izmišljeno ime Jakost Farmacevtsk a oblika
Packaging Content 
Ovojnina Vsebina Velikost pakiranja
Do not stop your treatment just because you feel better. 
Ne prenehajte z zdravljenjem samo zato, ker se počutite bolje.
You will probably need to lie down until you feel better. 
Najbrž se boste morali uleči, dokler se ne boste bolje počutili.
In some cases, these symptoms can lead to unconsciousness. 
V nekaterih primerih lahko ti simptomi vodijo v nezavest.
These events occurred in about 0.1 to 1.1% of patients. 
Te reakcije so se pojavljale pri približno 0,1 do 1,1 % bolnikov.
The absorption and elimination are complete approximately six to eight months after the last injection. 
Absorpcija in izločanje sta zaključena približno šest do osem mesecev po zadnjem injiciranju.
The injection should be performed with steady, continuous pressure. 
Injiciranje mora biti izvedeno s čvrstim, neprekinjenim pritiskanjem.
Slowly withdraw the desired amount. 
Počasi izvlecite želeno količino.
From a microbiological point of view, the product should be used immediately. 
Z mikrobiološkega vidika moramo zdravilo takoj uporabiti.
Information on long term safety is primarily limited to open-label, uncontrolled data. 
Informacije o dolgoročni varnosti so primarno omejene na nenadzorovane podatke iz odprtih študij.
Use in elderly (>75 years) 
Uporaba pri starejših (> 75 let)
The release becomes diminishingly smaller within eight to twelve weeks. 
Sproščanje postane oslabljeno v osmih do dvanajstih tednih.
It is important to note that there is more solvent in the vial than is needed to reconstitute. 
Pomembno je opozoriti, da je v viali več vehikla, kot ga je potrebno za rekonstitucijo.
For instructions for use, see section 6.6. 
Za navodila za uporabo, glejte poglavje 6.6.
The majority of these reactions was reported to be of “mild” to “moderate” severity. 
Večino teh učinkov so poročali kot “blagih” do “zmernih” glede resnosti.
Some excess product will remain in the vial. 
Nekaj presežnega zdravila bo ostalo v viali.
Due to biochemical and physiological modification and reduction of muscular mass, this formulation is not recommended to be started in this sub-group of patients. 
Glede na biokemijske in fiziološke spremembe ter zmanjšanje mišične mase, te oblike ne priporočamo pri tej podskupini bolnikov.
These symptoms typically resolve within 24 to 72 hours after your injection. 
Ti simptomi običajno minejo v 24 do 72 urah po vaši injekciji.
If you miss an injection, you should contact your doctor to arrange your next injection as soon as you can. 
Če ste izpustili injekcijo, morate poklicati vašega zdravnika, da se dogovorite za vašo naslednjo injekcijo kakor hitro je mogoče.
In most cases, initial signs and symptoms related to this reaction have appeared within 1 hour following injection, and in all cases full recovery was reported to have occurred within 24 - 72 hours after injection. 
V večini primerov so se začetni znaki in simptomi, povezani s tem učinkom, pojavili v 1 uri po injiciranju in v vseh primerih so poročali o popolnem okrevanju v 24 - 72 urah po injiciranju.
After insertion of the needle, aspirate for several seconds to ensure no blood appears. 
Po vbodu igle nekaj sekund aspirirajte za zagotovitev, da se ne pojavi kri.
The doctor or nurse may also want to measure your blood pressure and pulse. 
Zdravnik ali medicinska sestra vam bosta morda hotela tudi izmeriti vaš krvni tlak in srčno frekvenco.
Your doctor will decide how much ZYPADHERA you need and how often you need to be given an injection. 
Vaš zdravnik bo odločil, koliko zdravila ZYPADHERA potrebujete in kako pogosto morate prejeti injekcijo.
Contact your doctor or hospital straight away if you experience any of the above symptoms. 
Nemudoma pokličite vašega zdravnika ali bolnišnico, če imate katerikoli zgoraj navedeni simptom.
Although unlikely, you may get the symptoms more than 3 hours after the injection. 
Čeprav malo verjetno, lahko dobite simptome več kot 3 ure po injiciranju.
It is important that you carry on receiving ZYPADHERA for as long as your doctor has told you to. 
Pomembno je, da nadaljujete s prejemanjem zdravila ZYPADHERA tako dolgo, kot vam je povedal vaš zdravnik.
Select and prepare a site for injection in the gluteal area. 
Izberite in pripravite mesto za injiciranje v glutealnem področju.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 20-25°C. 
Če ga ne uporabimo takoj, so čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika in naj običajno ne presegajo 24 ur pri 20-25 °C.
There are no controlled data on maintenance of effect or long term safety (see sections 4.4 and 4.8). 
Nadzorovanih podatkov o vzdrževalnem učinku ali o dolgoročni varnosti ni (glejte poglavji 4.4 in 4.8).
Patients should be closely monitored during this period. 
V tem času je potrebno bolnike skrbno spremljati.
In order to identify the first ZYPADHERA dose for all patients the scheme in Table 1 should be considered. 
Za določitev prvega odmerka zdravila ZYPADHERA za vse bolnike, je potrebno upoštevati shemo v Tabeli 1.
During treatment dose may subsequently be adjusted on the basis of individual clinical status. 
Med zdravljenjem se lahko odmerek na podlagi individualnega kliničnega stanja kasneje prilagodi.
• increase in blood pressure 
• zvišan krvni tlak
However, the magnitude of the impact of gender, or smoking on olanzapine clearance is small in comparison to the overall variability between individuals. 
Vendar je vpliv spola ali kajenja na očistek olanzapina majhen v primerjavi s povprečno variabilnostjo med posamezniki.
• Tell the doctor or nurse if you feel dizzy or faint after the injection. 
• Povejte zdravniku ali medicinski sestri, če ste po injiciranju omotični ali se slabo počutite.
• Whenever the risk management system is modified, especially as the result of new information being received that may lead to a signficant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. 
• ob vsakršni spremembi sistema za obvladovanje tveganj, zlasti kadar je tovrstna sprememba posledica prejema novih informacij, ki lahko privedejo do znatne spremembe razmerja med koristmi in tveganji, ali kadar je ta sprememba posledica tega, da je bil dosežen pomemben mejnik (farmakovigilančni ali povezan z zmanjševanjem tveganja)
(Table 1) 
(Tabela 1)
Unsuspended: visible clumps Suspended: no clumps Figure B: Check for unsuspended powder and repeat tapping if needed. 
Nesuspendirano: vidne grude Suspendirano: brez grud Slika B: Preverite, da ni nesuspendiranega praška in po potrebi nadaljujte s stresanjem.
SN: {number} 
SN: {številka} NN: {številka}
ZYPADHERA can sometimes enter the bloodstream too quickly. 
Zdravilo ZYPADHERA lahko včasih prehitro preide v krvni obtok.
Discontinuation symptoms7, 12 
Odtegnitveni simptomi7, 12
Exacerbation was measured by worsening of items on the PANSS derived BPRS Positive scale and hospitalization due to worsening of positive psychotic symptoms. 
Poslabšanje so merili z slabšanjem točk PANSS, ki so jih dobili iz pozitivne lestvice BPRS ter iz hospitalizacije zaradi poslabšanja pozitivnih psihotičnih simptomov.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before being given this injection. 
Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte s svojim zdravnikom, preden vzamete to zdravilo.
Tell your doctor as soon as possible if any of the following applies to you: 
Čimprej povejte svojemu zdravniku, če se karkoli od naslednjega nanaša na vas:
Do not use this product if you notice discolouration or other visible signs of deterioration. 
Tega zdravila ne uporabite, če opazite spremembo barve ali druge vidne znake razpada.
Failure to follow these instructions may result in a needlestick injury. 
Neupoštevanje teh navodil lahko vodi v poškodovanje igle.
• Reconstitution and Administration card (this leaflet) 
• Kartico za rekonstitucijo in dajanje (to navodilo)
The suspended product will be yellow and opaque. 
Suspendirano zdravilo bo rumeno in neprozorno.
All 3 ZYPADHERA treatment groups showed statistically significantly greater improvement than placebo beginning by end of Week 1. 
Vse tri skupine zdravljenja z zdravilom ZYPADHERA so pokazale začetek statistično značilnega večjega izboljšanja kot placebo na koncu 1. tedna.
DO NOT MASSAGE THE INJECTION SITE. 
MESTA INJICIRANJA NE MASIRAJTE.
• excessive sleepiness 
• pretirana zaspanost
No oral antipsychotic supplementation was allowed. 
Dodajanje peroralnih antipsihotikov ni bilo dovoljeno.
Chemical and physical stability of the suspension in the vials has been demonstrated for 24 hours at 2025 °C. 
Suspenzija je kemijsko in fizikalno stabilna v viali 24 ur pri 20-25 °C.
INSTRUCTIONS FOR HEALTH CARE PROFESSIONALS 
NAVODILA ZA ZDRAVSTVENO OSEBJE
In a study of oral olanzapine given to Caucasians, Japanese, and Chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations. 
V študiji peroralnega olanzapina, ki so ga dali belcem, Japoncem in Kitajcem ni bilo razlik v farmakokinetičnih parametrih med temi tremi populacijami.
Your doctor should do blood tests to check blood sugar and certain fat levels before you start taking ZYPADHERA and regularly during treatment. 
Vaš zdravnik mora opraviti krvni test za preiskavo sladkorja v krvi in nivo določenih maščob pred začetkom jemanja zdravila ZYPADHERA in redno tekom zdravljenja.
Special care must be taken to apply appropriate injection technique to avoid inadvertent intravascular or subcutaneous injection (see section 6.6). 
Potrebna je posebna previdnost glede uporabe ustrezne tehnike injiciranja v izogib nenamernega intravaskularnega ali subkutanega injiciranja (glejte poglavje 6.6).
Final volume to inject (ml) 
Končni volumen za injiciranje (ml)
If you are already taking antidepressants, medicines for anxiety or to help you sleep (tranquillisers), you may feel drowsy if ZYPADHERA is given. 
Če že jemljete antidepresive, zdravila proti anksioznosti ali zdravila, ki vam pomagajo spati (pomirjevala), se boste po dajanju zdravila ZYPADHERA morda počutili zaspane.
Fertility Effects on fertility are unknown (see section 5.3 for preclinical information) 
Plodnost Učinki na plodnost niso znani (glejte poglavje 5.3 za predklinične podatke).
Reactions occurred rarely (<1 in 1,000 injections) between 1 and 3 hours, and very rarely (<1 in 10,000 injections) after 3 hours. 
Učinki so se redko pojavili (< 1 od 1.000 injiciranj) med 1 in 3 urami in zelo redko (< 1 od 10.000 injiciranj) po 3 urah.
− Promote awareness of appropriate metabolic monitoring by distributing utilized published antipsychotic guidelines 
Podpirati pomen ustreznega spremljanja presnove z razdeljevanjem koristnih, objavljenih antipsihotičnih smernic.
Water for injections Hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) 
Klorovodikova kislina (za prilagoditev pH) Natrijev hidroksid (za prilagoditev pH)
The vial is for single use only. 
Viala je samo za enkratno uporabo.
These results support efficacy for ZYPADHERA over 8 weeks of treatment and a drug effect that was observed as early as 1 week after starting treatment with ZYPADHERA. 
Ti rezultati podpirajo učinkovitost zdravila ZYPADHERA preko 8 tednov zdravljenja in učinkovitost zdravila, ki so ga opazili že 1 teden po začetku zdravljenja z zdravilom ZYPADHERA.
2) Recommendations for monitoring of patients for glucose, lipids, and weight 
2) Priporočila za spremljanje bolnikov glede glukoze, lipidov in telesne mase.
ZYPADHERA has not been systematically studied in elderly patients (> 65 years). 
Zdravila ZYPADHERA niso sistemsko preučevali pri starejših bolnikih (> 65 let).
As a routine precaution, if you are over 65 years your doctor may monitor your blood pressure. 
Kot običajen previdnostni ukrep vam lahko vaš zdravnik nadzoruje krvni tlak, če ste stari več kot 65 let.
Oral olanzapine was used as a flexible dose starting with 2.5 and ranging up to 20 mg/day. 
Olanzapin so uporabljali kot prilagodljiv odmerek, ki so ga začeli z 2,5 mg in zviševali do 20 mg/dan.
Discard the vials, syringe, used needles, extra needle and any unused solvent in accordance with appropriate clinical procedures. 
Zavrzite viale, injekcijsko brizgo, uporabljene igle, dodatno iglo in kakršenkoli neuporabljen vehikel v skladu z ustreznimi kliničnimi postopki.
Withdraw the pre-determined solvent volume (Step 2) into the syringe. 
Izvlecite predhodno določen volumen vehikla (Korak 2) v injekcijsko brizgo.
• been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye). 
• če so vam v preteklosti ugotovili težave z očmi, kot je določena vrsta glavkoma (povišan tlak v očesu).
Vial of suspension after reconstitution: 24 hours. 
Viala s suspenzijo po rekonstituciji: 24 ur.
Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and in vitro and oral in vivo mammalian tests. 
Olanzapin ni bil mutagen ali klastogen v širokem razponu standardnih testov, ki je vključeval teste mutiranja bakterij ter in vitro in in vivo teste na sesalcih.
In 44 patients with schizophrenia >65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events. 
Pri 44 bolnikih s shizofrenijo, starejših od 65 let, odmerjanje od 5 do 20 mg/dan ni bilo povezano s kakim razločevalnim profilom neželenih učinkov.
Withdraw air to equalize the pressure in the vial. 
Za izenačitev tlaka v viali spustite zrak.
The most commonly reported injection site related adverse reaction was pain. 
Najpogosteje poročani neželeni učinek na mestu injiciranja je bila bolečina.
The plasma protein binding of olanzapine is about 93% over the concentration range of 7 to about 1000 ng/mL. 
Vezava olanzapina na plazemske beljakovine je bila okoli 93 % v razponu koncentracij od približno 7 do približno 1000 ng/ml.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (EMA) http://www.ema.europa.eu
As olanzapine may cause somnolence and dizziness, patients should be cautioned about operating machinery, including motor vehicles. 
Ker olanzapin lahko povzroči zaspanost in omotičnost, je treba bolnike opozoriti na previdnost glede upravljanja s stroji, vključno z motornimi vozili.
Very rare side effects include serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). 
Zelo redki neželeni učinki vključujejo resne alergijske reakcije, kot je npr. reakcija na zdravilo z eozinofilijo in sistemskimi simptomi (DRESS).
Similar pharmacokinetic differences between males and females and smokers and non-smokers were observed in ZYPADHERA clinical trials. 
Podobno so opazovali farmakokinetične razlike med moškimi in ženskimi ter kadilci in nekadilci pri kliničnih preskušanjih z zdravilom ZYPADHERA.
• The use of ZYPADHERA in elderly patients with dementia (confusion and memory loss) is not recommended as it may have serious side effects. 
• Uporaba zdravila ZYPADHERA ni priporočljiva pri starejših bolnikih z demenco (zmedenost in izguba spomina), saj lahko povzroči resne neželene učinke.
However, systemic concentrations in these studies were generally less than that seen at effect levels in the oral studies; thus the information on oral olanzapine is provided below for reference. 
Vendar so bile sistemske koncentracije v teh študijah na splošno nižje kot tiste, ki so jih opazili na nivojih učinkovanja pri peroralnih študijah; zato kot referenco spodaj navajamo podatke za peroralni olanzapin.
When more than one factor is present which might result in slower metabolism (female gender, geriatric age, non-smoking status), consideration should be given to decreasing the dose. 
Ob navzočnosti več kot enega dejavnika, ki bi lahko prispeval k počasnejši presnovi (ženski spol, starostnik, nekadilec), je treba pretehtati znižanje odmerka.
Three Hypodermic safety needles. 
Tri podkožne varnostne igle.
In a review of safety data from clinical trials and spontaneous postmarketing reports, injection site abscess was rarely (≥ 1/10,000 to < 1/1,000) reported. 
Pri pregledu podatkov o varnosti iz kliničnih študij in spontanih poročil v obdobju trženja so o abcesu na mestu injiciranja poročali redko (≥ 1/10.000 do < 1/1.000).
Reconstituted ZYPADHERA remains stable for up to 24 hours in the vial. 
ZYPADHERA ostane v viali stabilno še do 24 ur.
Plasma concentrations remain measurable for several months after each ZYPADHERA injection. 
Plazemske koncentracije ostanejo merljive še nekaj mesecev po vsakem injiciranju zdravila ZYPADHERA.
16 Elevated plasma prolactin levels were reported in 47.4% of adolescent patients. 
16 O zvišanih plazemskih koncentracijah prolaktina so poročali pri 47,4 % mladostnikov.
After reconstitution in the vial: 24 hours. 
Po rekonstituciji viale: 24 ur.
• Parkinson's disease 
• Parkinsonova bolezen
Only remove the device with the engaged needle from the syringe when required by a specific medical procedure. 
Z injekcijske brizge odstranite pripomoček z nameščeno iglo samo, ko je to zahtevano po določenem zdravstvenem postopku.
Patients should be advised about this potential risk and the need to be observed for 3 hours in a healthcare facility each time ZYPADHERA is administered. 
Bolnike je potrebno opozoriti glede tega možnega tveganja in jih je potrebno po vsakem dajanju zdravila ZYPADHERA 3 ure opazovati v zdravstvenih ustanovah.
If this happens, you may have the symptoms listed below after your injection. 
Če se to zgodi, imate lahko po injiciranju simptome, ki so navedeni spodaj.
• carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepressant) or ciprofloxacin (an antibiotic) - it may be necessary to change your ZYPADHERA dose. 
• karbamazepin (antiepileptik in stabilizator razpoloženja), fluvoksamin (antidepresiv) ali ciprofloksacin (antibiotik) - morda bo potrebno spremeniti vaš odmerek zdravila ZYPADHERA.
After each injection you will be observed in your healthcare facility for at least 3 hours for the symptoms listed above. 
Po vsakem injiciranju vas bodo v vaši zdravstveni ustanovi najmanj 3 ure opazovali za pojav simptomov, naštetih zgoraj.
If this happens after you have been given ZYPADHERA, tell your doctor or nurse immediately. 
Če se vam to zgodi potem, ko ste prejeli zdravilo ZYPADHERA, nemudoma povejte svojemu zdravniku ali medicinski sestri.
Tap the vial firmly and repeatedly on a hard surface until no powder is visible. 
Vialo dobro stresite ob trdo površino in ponavljajte, dokler ni vidnega nič praška.
You should not be given this injection if you are breast-feeding as small amounts of olanzapine can pass into breast milk. 
Ko dojite, injekcij ne smete dobivati, ker lahko majhne količine olanzapina prehajajo v materino mleko.
In cytopenic dogs, there were no undesirable effects on progenitor and proliferating cells in the bone marrow. 
Pri psih z izraženo citopenijo ni bilo neželenih učinkov na progenitorne in proliferirajoče celice v kostnem mozgu.
Controlled efficacy data in adolescents (ages 13 to 17 years) are limited to short term oral olanzapine studies in schizophrenia (6 weeks) and mania associated with bipolar I disorder (3 weeks), involving less than 200 adolescents. 
Nadzorovani podatki o učinkovitosti pri mladostnikih (starih 13 do 17 let) so omejeni na kratkoročne študije peroralnega olanzapina pri shizofreniji (6 tednov) in maniji povezani z bipolarno I motnjo (3 tedni), ki vključujejo manj kot 200 mladostnikov.
Immediately prior to leaving the health care facility, it should be confirmed that the patient is alert, oriented, and absent of any signs and symptoms of overdose. 
Tik pred odhodom iz zdravstvene ustanove mora biti potrjeno, da je bolnik buden, orientiran in da nima znakov in simptomov prevelikega odmerjanja.
Fatal outcomes have been reported for acute oral overdoses as low as 450 mg but survival has also been reported following acute overdose of approximately 2 g of oral olanzapine. 
Poročali so o smrtnih izidih pri akutnih peroralnih prevelikih odmerjanjih tako nizkih odmerkov, kot je 450 mg, vendar so poročali tudi o preživetju po akutnem prevelikem odmerjanju z odmerkom približno 2 g peroralnega olanzapina.
Inject the solvent volume into the powder vial. 
Injicirajte volumen vehikla v vialo s praškom.
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10). 
Našteti izrazi pogostnosti so definirani kot sledi: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10).